Jefferies on Cytokinetics (CYTK): 'we await some indication that these initiatives will deliver the intended results'
Tweet Send to a Friend
Jefferies analyst Akash Tewari reiterated a Buy rating and $80.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst comments "We caught ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
